ClinicalTrials.gg

Program

axicabtagene ciloleucel

Also written as “Axicabtagene Ciloleucel”, “Axicabtagene ciloleucel” and “KTE-C19”.

Its studies are mostly in Lymphoma, B-Cell · Lymphoma, Follicular · Lymphoma, Large B-Cell, Diffuse, led by Gilead Sciences.

Furthest: phase 3, since Dec 21, 201710 company-led studies, 3 open or runningNext primary completion: Oct 2030 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences103 open or runningphase 3since Dec 21, 2017Oct 5, 2016Oct 2030phase 3 · NCT05371093

Also a collaborator on its studies: Hoffmann-La Roche and Humanigen.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 5, 2016First study: phase 2 study in Lymphoma, Large B-Cell, DiffuseFirst studyNCT02926833 · 37 enrolled · United States
  2. Apr 3, 2017Phase 2 study in Lymphoma, FollicularNCT03105336 · 159 enrolled · United States, France
  3. Dec 21, 2017Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT03391466 · 359 enrolled · United States, Australia, Austria and more
  4. Nov 29, 2018Phase 2 study in Lymphoma, B-CellNCT03761056 · 42 enrolled · United States, Australia, France
  5. Jun 27, 2019Phase 2 study in Refractory Large B-cell LymphomaNCT04002401 · 27 enrolled · United States
  6. Mar 17, 2020Phase 1 study in RecurrenceNCT04314843 · 6 enrolled · United States
  7. May 9, 2022Phase 3 study in Lymphoma, FollicularNCT05371093 · 231 enrolled · United States, France, Germany and more
  8. Jul 13, 2022Phase 2 study in RecurrenceNCT05459571 · 35 enrolled · United States
  9. Oct 31, 2022Phase 3 study in High-risk Large B-cell Lymphoma (LBCL)NCT05605899 · 300 enrolled · United States, Australia, Austria and more
  10. Mar 13, 2026Phase 3 study in RecurrenceNCT07479797 · 550 enrolled · United States, Australia, Belgium and more

Ahead

  1. Oct 2030Primary completion: phase 3 study in Lymphoma, FollicularNCT05371093
  2. Mar 2031Primary completion: phase 3 study in High-risk Large B-cell Lymphoma (LBCL)NCT05605899
  3. May 2031Primary completion: phase 3 study in RecurrenceNCT07479797

TargetBeta

CD19 →read by rule
“B-lymphocyte antigen CD19 binding agent”ChEMBL 37, by rule

Other programs on CD19

ProgramCompanyFurthest phaseStudies
blinatumomabruleAmgenphase 429
inebilizumabruleAmgenphase 419
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012FAstraZenecaphase 312
surovatamigAstraZenecaphase 310
lisocabtagene maraleucelruleBristol-Myers Squibbphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
obexelimabzenas-biopharma-usa-llcphase 37
Autologous Anti-CD19 CAR-T Cells CABA-201rulecabaletta-biophase 36
zolacabtagene autoleucelBristol-Myers Squibbphase 36
Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753ruleGilead Sciencesphase 32
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32
rapcabtagene autoleucelNovartisphase 28

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07479797Recurrence · United States, Australia, Belgium and more3Active, not recruitingMay 2031550
NCT05605899High-risk Large B-cell Lymphoma (LBCL) · United States, Australia, Austria and more3Active, not recruitingMar 2031300
NCT05459571Recurrence · United States2CompletedNov 24, 202535
NCT05371093Lymphoma, Follicular · United States, France, Germany and more3Active, not recruitingOct 2030231
NCT04314843Recurrence · United States1TerminatedMar 16, 20216
NCT04002401Refractory Large B-cell Lymphoma · United States2CompletedJan 30, 202327
NCT03761056Lymphoma, B-Cell · United States, Australia, France2CompletedOct 12, 202342
NCT03391466Lymphoma, Large B-Cell, Diffuse · United States, Australia, Austria and more3CompletedMar 18, 2021359
NCT03105336Lymphoma, Follicular · United States, France2CompletedDec 20, 2024159
NCT02926833Lymphoma, Large B-Cell, Diffuse · United States2CompletedJan 12, 202337

How it is read

Names in the registry

  • “Axicabtagene Ciloleucel”, 8 entries
  • “Axicabtagene ciloleucel”, 1 entry
  • “KTE-C19”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.